• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Zura Bio Limited

    7/16/25 9:34:25 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ZURA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    ZURA BIO LIMITED

    (Name of Issuer)


    Class A Ordinary Shares

    (Title of Class of Securities)


    G9TY5A101

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    G9TY5A101


    1Names of Reporting Persons

    JPMORGAN CHASE & CO.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    4,672,416.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    4,672,416.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,672,416.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.5 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    ZURA BIO LIMITED
    (b)Address of issuer's principal executive offices:

    1489 W. Warm Springs Rd. #110 Henderson NV 89014
    Item 2. 
    (a)Name of person filing:

    JPMORGAN CHASE & CO.
    (b)Address or principal business office or, if none, residence:

    383 Madison Avenue,, New York, NY 10179
    (c)Citizenship:

    DE
    (d)Title of class of securities:

    Class A Ordinary Shares
    (e)CUSIP No.:

    G9TY5A101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    4672416
    (b)Percent of class:

    7.5  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    4672416

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    4672416

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    J.P. MORGAN SECURITIES PLC; J.P. MORGAN SECURITIES LLC
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.


    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    JPMORGAN CHASE & CO.
     
    Signature:Rachel Tsvaygoft
    Name/Title:Vice President
    Date:07/16/2025
    Get the next $ZURA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZURA

    DatePrice TargetRatingAnalyst
    11/4/2024$15.00Outperform
    Leerink Partners
    9/5/2024$5.00Neutral
    H.C. Wainwright
    5/3/2024$26.00Overweight
    Piper Sandler
    10/10/2023$10.00Buy
    Ladenburg Thalmann
    8/25/2023$17.00Outperform
    Oppenheimer
    6/22/2023$20.00Buy
    Guggenheim
    6/14/2023$14.00Buy
    Chardan Capital Markets
    5/24/2023$20.00Strong Buy
    Raymond James
    More analyst ratings

    $ZURA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Ploos Van Amstel Arnout bought $496,000 worth of Class A ordinary shares (80,000 units at $6.20), increasing direct ownership by 400% to 100,000 units (SEC Form 4)

    4 - Zura Bio Ltd (0001855644) (Issuer)

    5/23/24 8:53:36 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Howell Michael bought $24,999 worth of Class A ordinary shares (7,987 units at $3.13) (SEC Form 4)

    4 - Zura Bio Ltd (0001855644) (Issuer)

    4/24/24 6:54:25 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Nistala Kiran bought $10,000 worth of Class A ordinary shares (3,195 units at $3.13) (SEC Form 4)

    4 - Zura Bio Ltd (0001855644) (Issuer)

    4/24/24 6:53:25 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ZURA
    SEC Filings

    View All

    Zura Bio Limited filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Zura Bio Ltd (0001855644) (Filer)

    8/20/25 7:03:35 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Zura Bio Limited

    SCHEDULE 13G/A - Zura Bio Ltd (0001855644) (Subject)

    8/14/25 5:52:58 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Zura Bio Limited

    10-Q - Zura Bio Ltd (0001855644) (Filer)

    8/14/25 8:25:59 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ZURA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Hyllengren Eric J

    4 - Zura Bio Ltd (0001855644) (Issuer)

    7/17/25 5:20:07 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Hyllengren Eric J

    3 - Zura Bio Ltd (0001855644) (Issuer)

    7/17/25 5:18:43 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Becker Daniel J.

    4 - Zura Bio Ltd (0001855644) (Issuer)

    5/29/25 9:39:50 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ZURA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zura Bio to Participate in the Cantor Fitzgerald Global Healthcare Conference

    Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet needs, today announced that its senior leadership team will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 4, 2025, at 2:45 PM ET in New York, NY. The Company will also conduct one-on-one investor meetings on the same day. A live webcast of the presentation will be available in the Investors section of the Company's website under News & Events. A replay will remain archived for at least 30 days. ABOUT ZURA BIO Zura Bio is a

    8/20/25 6:30:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates

    Initiated TibuSHIELD, a global Phase 2 clinical study evaluating tibulizumab in adults with moderate to severe hidradenitis suppurativa (HS) in Q2 2025 Continued progress in the Phase 2 TibuSURE clinical study evaluating tibulizumab in adults with systemic sclerosis (SSc) Appointed new executive and board leadership to support ongoing growth and development Reported $154.5 million in cash and cash equivalents as of June 30, 2025; expected to fund planned operations through 2027 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a clinical-stage, multi-asset immunology company dedicated to developing novel dual-pathway antibodies for autoimmune and inflammatory diseas

    8/14/25 8:15:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today reported that on July 15, 2025, the Company granted inducement awards consisting of options to purchase up to 890,950 Class A Ordinary Shares (the "Options") to seven newly hired employees, which includes an award of 672,000 Options granted to Eric Hyllengren, the newly appointed Chief Financial Officer. These awards were approved by the Compensation Committee and the Board and granted outside the Company's 2023 Equity Incentive Plan (the "Plan"), with a grant date of July 15, 2025,

    7/17/25 4:30:00 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ZURA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on Zura Bio Limited with a new price target

    Leerink Partners initiated coverage of Zura Bio Limited with a rating of Outperform and set a new price target of $15.00

    11/4/24 7:45:03 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Zura Bio Limited with a new price target

    H.C. Wainwright initiated coverage of Zura Bio Limited with a rating of Neutral and set a new price target of $5.00

    9/5/24 8:35:06 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler initiated coverage on Zura Bio Limited with a new price target

    Piper Sandler initiated coverage of Zura Bio Limited with a rating of Overweight and set a new price target of $26.00

    5/3/24 7:45:08 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ZURA
    Leadership Updates

    Live Leadership Updates

    View All

    Zura Bio Announces Chief Financial Officer Transition

    Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 7, 2025. He will succeed Verender Badial, who will step down from the role and remain with the company as a non-executive employee through July 31, 2025, to support a seamless transition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250701021645/en/Eric Hyllengren Mr. Badial joined Zura Bio in March 2023, at the time of its business combination with

    7/1/25 6:30:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights

    Presented data for tibulizumab at EULAR 2024, highlighting the potential relevance of dual-inhibition of both IL-17A and BAFF in autoimmune and inflammatory diseases Expect to initiate Phase 2 studies evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in 4Q 2024 and hidradenitis suppurativa (HS) in 2Q 2025 Strengthened management and advisory team with appointment of Robert Lisicki as CEO & formation of Scientific Advisory Board Cash, cash equivalents and investments of $188.4 million as of June 30, 2024, including $112.5 million from private placement executed in April 2024, anticipated to support operations as currently planned through 2027 Zura Bio Limited

    8/13/24 9:21:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer

    Significant 2023 milestones highlighted by successful Nasdaq listing, leadership team buildout, formation of strategic development and scientific plan On track to initiate Phase 2 study evaluating tibulizumab (ZB-106) for the treatment of systemic sclerosis (SSc) in 2H 2024 Appointment of CEO, Robert Lisicki, underscores Zura Bio's commitment to building leading immunology company as we prioritize excellence in strategic development and scientific planning Outgoing Founder and CEO, Someit Sidhu, M.D., will continue as a Board Director to leverage institutional knowledge and provide continued support Cash position as of December 31, 2023 totaling $99.8 million in cash, cash equi

    3/28/24 6:00:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ZURA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Zura Bio Limited

    SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

    11/14/24 5:52:59 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zura Bio Limited

    SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

    11/14/24 5:06:21 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Zura Bio Limited

    SC 13G - Zura Bio Ltd (0001855644) (Subject)

    11/14/24 4:47:14 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ZURA
    Financials

    Live finance-specific insights

    View All

    Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

    Achieved key milestones in 2024 that enhanced our leadership team, strengthened our financial position, and progressed our clinical pipeline Initiated the Phase 2 TibuSURE trial in adults with systemic sclerosis (SSc) Completed a $112.5 million private placement financing in April 2024, contributing to a total of $176.5 million in cash and cash equivalents, as of December 31, 2024 Cash runway anticipated through 2027, supporting operations and funding anticipated tibulizumab data readouts in SSc and hidradenitis suppurativa (HS) Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for

    3/25/25 6:30:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

    Expect to initiate Phase 2 studies evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in Q4 2024 and hidradenitis suppurativa (HS) in Q2 2025 Cash, cash equivalents and investments totaling $188.2 million as of September 30, 2024, are anticipated to support operations, as currently planned, through 2027 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported financial results for the third quarter of 2024 and recent corporate updates. "In the third quarter of 2024, we made significant progress toward initiating our first Phase 2 tria

    11/7/24 6:30:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights

    Initiating Phase 2 clinical trials in 2024 to evaluate ZB-106 (tibulizumab) in systemic sclerosis and hidradenitis suppurativa, and ZB-168 in alopecia areata Experienced team building the next Immunology leader Cash position of $103.9 million in cash, cash equivalents and investments is expected to support development and operations into 2026 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio") a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced its financial results for the quarter ended September 30, 2023, and recent business highlights. "In the third quarter, Zura Bio made significant progress

    11/13/23 6:30:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care